These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31172720)

  • 41. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Single Institution Retrospective Study of the Clinical Efficacy of Tiotropium Respimat in Never-Smoking Elderly Asthmatics with Irreversible Airflow Limitation.
    Hara J; Kasahara K; Ohkura N; Yamamura K; Sakai T; Abo M; Ogawa N; Saeki K; Koba H; Watanabe S; Uchida Y; Tambo Y; Sone T; Kimura H
    Drug Res (Stuttg); 2019 Apr; 69(4):211-217. PubMed ID: 30193393
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomised trial of once-daily vilanterol in children with asthma on inhaled corticosteroid therapy.
    Oliver AJ; Covar RA; Goldfrad CH; Klein RM; Pedersen SE; Sorkness CA; Tomkins SA; Villarán C; Grigg J
    Respir Res; 2016 Apr; 17():37. PubMed ID: 27044326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of salmeterol/fluticasone propionate versus fluticasone propionate in asthma patients: a randomized, double-blind study.
    Lee YS; Lin HC; Huang CD; Lee KY; Liu CY; Yu CT; Wang CH; Kuo HP
    Chang Gung Med J; 2011; 34(4):382-94. PubMed ID: 21880193
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
    Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.
    Hashimoto S; Ikeuchi H; Murata S; Kitawaki T; Ikeda K; Banerji D
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2543-2551. PubMed ID: 27785010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Burden of Asthma and Role of 2.5 µg Tiotropium Respimat
    Mansfield L; Duong-Quy S; Craig T
    Adv Ther; 2019 Oct; 36(10):2587-2599. PubMed ID: 31435830
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study.
    O'Byrne PM; D'Urzo T; Beck E; Fležar M; Gahlemann M; Hart L; Blahova Z; Toorawa R; Beeh KM
    Respir Res; 2015 Aug; 16(1):97. PubMed ID: 26283085
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
    Tang Y; Massey D; Zhong NS
    Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Forced Expiratory Flow (FEF
    Szefler SJ; Goldstein S; Vogelberg C; Bensch GW; Given J; Jugovic B; Engel M; Moroni-Zentgraf PM; Sigmund R; Hamelmann EH
    Pulm Ther; 2020 Dec; 6(2):151-158. PubMed ID: 32399899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
    Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
    Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat
    Beeh KM; Kirsten AM; Dusser D; Sharma A; Cornelissen P; Sigmund R; Moroni-Zentgraf P; Dahl R
    J Aerosol Med Pulm Drug Deliv; 2016 Oct; 29(5):406-415. PubMed ID: 26859538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
    Kerstjens HA; Disse B; Schröder-Babo W; Bantje TA; Gahlemann M; Sigmund R; Engel M; van Noord JA
    J Allergy Clin Immunol; 2011 Aug; 128(2):308-14. PubMed ID: 21636120
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies.
    D'Urzo A; Kerwin E; Overend T; D'Andrea P; Chen H; Goyal P
    Curr Med Res Opin; 2014 Mar; 30(3):493-508. PubMed ID: 24156566
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tiotropium versus placebo for inadequately controlled asthma: a meta-analysis.
    Tian JW; Chen JW; Chen R; Chen X
    Respir Care; 2014 May; 59(5):654-66. PubMed ID: 24170916
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO
    Ferguson GT; Karpel JP; Clerisme-Beaty E; Grönke L; Voß F; Buhl R
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2701-2710. PubMed ID: 27843306
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial.
    Brown MN; Fuhr R; Beier J; Su HL; Chen Y; Forsman H; Hamrén UW; Jackson H; Aggarwal A
    Respir Res; 2019 Feb; 20(1):37. PubMed ID: 30777086
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
    Wenzel S; Castro M; Corren J; Maspero J; Wang L; Zhang B; Pirozzi G; Sutherland ER; Evans RR; Joish VN; Eckert L; Graham NM; Stahl N; Yancopoulos GD; Louis-Tisserand M; Teper A
    Lancet; 2016 Jul; 388(10039):31-44. PubMed ID: 27130691
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.
    Decramer ML; Chapman KR; Dahl R; Frith P; Devouassoux G; Fritscher C; Cameron R; Shoaib M; Lawrence D; Young D; McBryan D;
    Lancet Respir Med; 2013 Sep; 1(7):524-33. PubMed ID: 24461613
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.